Genetically Engineered T-cells for B Cell Malignancies

 

Related Videos (117)

In this compelling video, hematologist-oncologist David L. Porter, MD, describes the development at the renowned Abramson Cancer Center of treatments for refractory chronic and acute lymphocytic leukemia involving genetically modified autologous T cells carrying chimeric antigen receptors (CAR) for the B lymphocyte antigen CD19. Dr. Porter reviews the clinical trials, documents the dramatic outcomes in patients with CLL and ALL arising from CAR T cell immunotherapy, and offers insight into the future of the therapy.

 

Penn PhysicianLink®

Penn PhysicianLink® is an exclusive program that helps all referring physicians connect with Penn Medicine. This comprehensive package of support services expedites and facilitates direct physician communication for patient consults, referrals and transfers.

Learn more about Penn PhysicianLink®